• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Artelo Biosciences Inc. (Amendment)

    2/23/22 4:36:39 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARTL alert in real time by email
    SC 13G/A 1 c103099_sc13ga.htm
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. 1)*
     

    Artelo Biosciences, Inc.

    (Name of Issuer)
     

    Common Stock, $0.001 par value

    (Title of Class of Securities)
     

    04301G201

    (CUSIP Number)
     

    December 31, 2021

    (Date of event which requires filing of this statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    o Rule 13d-1(b)
    x Rule 13d-1(c)
    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
    CUSIP No. 04301G201    
         
    1

    NAMES OF REPORTING PERSONS

    Iroquois Capital Management L.L.C.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

     

    6

    SHARED VOTING POWER

    100,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

    7

    SOLE DISPOSITIVE POWER

     

    8

    SHARED DISPOSITIVE POWER

    100,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    100,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.24% (See Item 4)*

     

    12

    TYPE OF REPORTING PERSON

    OO

     

                                                                         
     
    CUSIP No. 04301G201    
         
    1

    NAMES OF REPORTING PERSONS

    Richard Abbe

     

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

     

    6

    SHARED VOTING POWER

    100,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

    7

    SOLE DISPOSITIVE POWER

     

    8

    SHARED DISPOSITIVE POWER

    100,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    100,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.24% (See Item 4)*

     

    12

    TYPE OF REPORTING PERSON

    IN; HC

                                                                           
     
    CUSIP No. 04301G201    
         
    1

    NAMES OF REPORTING PERSONS

    Kimberly Page

     

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

     

    6

    SHARED VOTING POWER

    100,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

    7

    SOLE DISPOSITIVE POWER

     

    8

    SHARED DISPOSITIVE POWER

    100,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    100,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.24% (See Item 4)*

     

    12

    TYPE OF REPORTING PERSON

    IN

                                                                           
     
    CUSIP No. 04301G201    
         

    This Amendment No. 1 (this “Amendment”) amends the statement on Schedule 13G filed on October 19, 2020 (the “Original Schedule 13G”) with respect to the Common Stock, $0.001 par value (the “Common Stock”) of Artelo Biosciences, Inc. (the “Company”). Capitalized terms used herein and not otherwise defined in this Amendment have the meanings set forth in the Original Schedule 13G. This Amendment amends and restates each of Item 4 and Item 5 in its entirety as set forth below.

     

    Item 4. OWNERSHIP.
       
     

    The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 42,301,013 shares issued and outstanding as of January 10, 2022 as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended November 30, 2021, filed by the Issuer with the SEC on January 12, 2022, and assumes the exercise of the Company’s reported warrants (the “Reported Warrants”).

     

    As of the date of the event which requires filing of this statement, Iroquois Master Fund Ltd. (“Iroquois Master Fund”) held Reported Warrants to purchase 100,000 shares of Common Stock. Mr. Abbe shares authority and responsibility for the investments made on behalf of Iroquois Master Fund with Ms. Kimberly Page, each of whom is a director of the Iroquois Master Fund. As such, Mr. Abbe and Ms. Page may each be deemed to be the beneficial owner of all shares of Common Stock held by Iroquois Master Fund. Iroquois Capital is the investment advisor for Iroquois Master Fund and Mr. Abbe is the President of Iroquois Capital. As such, Mr. Abbe may be deemed to be the beneficial owner of all shares of Common Stock held by Iroquois Master Fund. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of shares of Common Stock owned by another Reporting Person. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such shares of Common Stock except to the extent of their pecuniary interest therein.

     
    CUSIP No. 04301G201    

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:  x

     

    Item 10. CERTIFICATION.
       
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     
    CUSIP No. 04301G201    

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 22, 2022

     

      IROQUOIS CAPITAL MANAGEMENT L.L.C.  
         
      By:   /s/ Richard Abbe
     
     
      Richard Abbe, President  
         
        /s/ Richard Abbe
     
     
      Richard Abbe  
         
        /s/ Kimberly Page
     
     
      Kimberly Page  
     
    Get the next $ARTL alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ARTL

    DatePrice TargetRatingAnalyst
    7/8/2025$20.00Hold → Buy
    D. Boral Capital
    11/1/2021$4.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ARTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by President, CEO, CFO, Treasurer Gorgas Gregory D.

      4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)

      7/7/25 4:40:52 PM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Favorito Tamara A

      4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)

      5/5/25 5:24:07 PM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Matsui Connie

      4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)

      5/5/25 5:21:52 PM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARTL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium

      SOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced the presentation of preclinical data in an osteaoarthritis (OA) pain model on its lead fatty acid binding protein 5 (FABP5) inhibitor, ART26.12, at the 35th Annual International Cannabinoid Research Society (ICRS) Symposium, being held July 6–10 in Bloomington, Indiana. The presentation, titled "The Fatty Acid Binding Protein 5 Inhibitor ART26.12 Alleviates Osteoarthritis Pain," was delivered

      7/9/25 7:50:00 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model

      ART12.11, the Patented CBD:TMP Cocrystal, Demonstrates Potent Antidepressant-Like Activity and Cognitive Benefits Over Leading SSRI Data Being Presented at the 35th Annual International Cannabinoid Research Society Symposium SOLANA BEACH, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced the presentation of compelling new preclinical data on its Cannabidiol (CBD) and Tetramethylpyrazine (TMP) cocrystal drug candidate, ART12.11, at the 35th Annual Internat

      7/7/25 7:45:00 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

      First Orally Active Fatty Acid Binding Protein 5 Inhibitor Evaluated in Humans First-in-Class Approach Targets Unmet Need in Multibillion-Dollar Pain Management Market SOLANA BEACH, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced favorable results from its first-in-human study evaluating ART26.12, a novel inhibitor of Fatty Acid Binding Protein 5 (FABP5). The results affirm the promising safety and pharmacokinetic (PK) profile previously observed in pre

      6/30/25 7:45:00 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARTL
    SEC Filings

    See more
    • Artelo Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

      7/18/25 4:35:54 PM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Artelo Biosciences Inc.

      424B5 - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

      7/18/25 4:35:46 PM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Artelo Biosciences Inc.

      EFFECT - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

      7/18/25 12:15:09 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Artelo Biosciences upgraded by D. Boral Capital with a new price target

      D. Boral Capital upgraded Artelo Biosciences from Hold to Buy and set a new price target of $20.00

      7/8/25 8:21:40 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Artelo Biosciences with a new price target

      HC Wainwright & Co. initiated coverage of Artelo Biosciences with a rating of Buy and set a new price target of $4.00

      11/1/21 6:29:39 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LADENBURG THALM/SH SH initiated coverage on Artelo Biosciences

      LADENBURG THALM/SH SH initiated coverage of Artelo Biosciences with a rating of Buy

      2/12/21 7:33:23 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARTL
    Leadership Updates

    Live Leadership Updates

    See more
    • Kintara Therapeutics Appoints Tamara A. Seymour to Board of Directors

      SAN DIEGO, May 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Tamara A. Seymour to the Company's Board of Directors replacing John Liatos, who will continue in his role as Kintara's Senior Vice President of Business Development. "We are delighted to welcome Tamara to the Board of Directors as she brings exceptional healthcare sector experience as an accomplished financial and operational executive," comm

      5/4/21 8:00:00 AM ET
      $KTRA
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors

      LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced the appointment of Tamara A. Seymour, CPA, to the Company’s board of directors. “We are pleased to welcome Tamara to Artelo’s board of directors,” said Connie Matsui, Board Chair. “Tamara brings with her an impressive track record in corporate finance and capital markets, as well as extensive experience guiding biopharmaceutical and diagnostic companies from clinical stage to commercialization. We believe her advice a

      3/9/21 8:30:00 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Artelo Biosciences Announces Appointment of Andrew Yates, Ph.D. as Senior Vice President and Chief Scientific Officer

      LA JOLLA, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the appointment of Andrew Yates, Ph.D, as Senior Vice President and Chief Scientific Officer. Dr. Yates is an experienced senior pharmaceutical executive, having served most recently at AstraZeneca, in significant roles across a number of functional areas including development and commercial strategy, medical affairs, and business development. Notably, Dr. Yates has been extensively involved in the life-cycle managem

      2/16/21 8:30:00 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Artelo Biosciences Inc. (Amendment)

      SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)

      2/23/22 4:36:39 PM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Artelo Biosciences Inc. (Amendment)

      SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)

      2/9/22 11:08:31 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Artelo Biosciences Inc. (Amendment)

      SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)

      2/4/22 3:19:12 PM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care